Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding...
EXTON, Pa., Feb. 11, 2021 /PRNewswire/ -- With the recent additions of Novartis' Mayzent, Bristol Myers Squibb's Zeposia, and Biogen's Vumerity to the multiple sclerosis (MS) marke…
